In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Health Care Reform: Raising the Innovation Threshold

Executive Summary

New reference price groups will include both patented and off-patent substances within the same class. Proving true innovation will be the only way to command premium prices. That won't be easy.
Advertisement

Related Content

Pricing Experiments: Pharmas Get Creative in Germany
Pricing Experiments: Pharmas Get Creative in Germany
Pfizer Gets Closer to Customers
Pfizer Gets Closer to Customers
How Biopharma Can Flourish in a Deteriorating Environment
How Biopharma Can Flourish in a Deteriorating Environment
Innovation: Defined by the Customer, Not by Pharma
Novartis/Hexal: Generic Consolidation, and More
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Indian Generics: Growing in Europe

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel